Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Up 418.6% in May

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 413,714 shares, an increase of 418.6% from the April 30th total of 79,768 shares. Based on an average daily trading volume, of 1,160,884 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

Several analysts have commented on CLPBY shares. Sanford C. Bernstein upgraded Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. Kepler Capital Markets upgraded Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. Finally, The Goldman Sachs Group downgraded Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Coloplast A/S presently has a consensus rating of “Hold”.

Coloplast A/S Price Performance

CLPBY stock traded down $0.18 during mid-day trading on Thursday, reaching $6.20. 28,664 shares of the company’s stock were exchanged, compared to its average volume of 571,895. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.30 and a quick ratio of 0.81. Coloplast A/S has a 12-month low of $6.10 and a 12-month high of $10.03. The stock’s 50 day moving average is $6.56 and its 200 day moving average is $7.75. The company has a market cap of $13.97 billion, a price-to-earnings ratio of 44.29, a price-to-earnings-growth ratio of 1.99 and a beta of 0.15.

Coloplast A/S (OTCMKTS:CLPBY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.11 billion. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. On average, research analysts expect that Coloplast A/S will post 0.4 EPS for the current year.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.